Shield Therapeutics (LON:STX) Share Price Passes Below 50-Day Moving Average – Should You Sell?
by Amy Steele · The Cerbat GemShares of Shield Therapeutics plc (LON:STX – Get Free Report) passed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of GBX 10.72 and traded as low as GBX 9.50. Shield Therapeutics shares last traded at GBX 9.96, with a volume of 2,648,759 shares trading hands.
Analyst Ratings Changes
Separately, Peel Hunt reaffirmed a “buy” rating and issued a GBX 15 price target on shares of Shield Therapeutics in a report on Friday, November 7th. One research analyst has rated the stock with a Buy rating, According to data from MarketBeat, Shield Therapeutics presently has an average rating of “Buy” and an average price target of GBX 15.
Read Our Latest Stock Analysis on Shield Therapeutics
Shield Therapeutics Price Performance
The stock has a market capitalization of £106.36 million, a PE ratio of -4.98 and a beta of 1.42. The company has a debt-to-equity ratio of 3,691.50, a current ratio of 1.05 and a quick ratio of 2.16. The stock’s fifty day moving average is GBX 10.72 and its 200-day moving average is GBX 8.20.
About Shield Therapeutics
Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.